P752: TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS
M. Wobus,
E. Balaian,
M. Lissner,
R. Towers,
U. Oelschlägel,
R. Wehner,
T. Chavakis,
M. Törngren,
H. Eriksson,
E. Bondesson,
U. Platzbecker,
M. Bornhäuser,
K. Sockel
Affiliations
M. Wobus
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
E. Balaian
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
M. Lissner
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
R. Towers
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
U. Oelschlägel
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
R. Wehner
2 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg
T. Chavakis
4 Institute of Clinical Chemistry and Laboratory Medicine, University Hospital TU Dresden, Dresden, Germany
M. Törngren
5 Active Biotech AB, Lund, Sweden
H. Eriksson
5 Active Biotech AB, Lund, Sweden
E. Bondesson
5 Active Biotech AB, Lund, Sweden
U. Platzbecker
6 Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
M. Bornhäuser
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
K. Sockel
1 Department of Medicine 1, University Hospital TU Dresden, Dresden
